EyeD Pharma

EyeD Pharma is a private, clinical-stage biotech based in Liège, Belgium, focusing on novel drug delivery for ophthalmology. Its core technology platform involves sustained-release polymeric micro-implants designed to enhance patient compliance and reduce side effects associated with traditional eye drop regimens. The pipeline includes programs for glaucoma (TimoD in Phase I), dry eye disease (HydraD in pre-clinical), and back-of-the-eye inflammation (InflammaD in feasibility), targeting large, growing patient populations. With over 100 employees and an internal CDMO, the company pursues a fully integrated development and manufacturing strategy.

Proprietary sustained-release drug delivery platform based on polymeric micro-implants and inserts for intraocular and ocular surface administration, supported by an internal, patented CDMO for manufacturing.

EyeD Pharma competes in the sustained-release ophthalmic drug delivery space against companies like Ocular Therapeutix (Dextenza, sustained-release implants), Alimera Sciences (Iluvien), and numerous others developing punctal plugs, injectable depots, and refillable implants. It differentiates through its fully integrated model and focus on specific micro-implant technology.